RXi Pharmaceuticals (NASDAQ: [[ticker:RXII]]), a Worcester, MA-based developer of RNA interference treatments, said today it will collaborate with Waltham, MA-based EyeGate Pharma to deliver RNAi therapeutics to the eye for retinal disorders. Financial details weren’t given, but the partnership combines EyeGate’s expertise in delivering drugs into the eye non-invasively with RXi’s technology and resources in RNAi drugs and delivery methods. EyeGate raised a round of equity financing last December, while RXi appointed a new CEO, Noah Beerman, in November and raised $16.2 million in a stock sale in March 2010.
Author: Gregory T. Huang
Greg is a veteran journalist who has covered a wide range of science, technology, and business. As former editor in chief, he overaw daily news, features, and events across Xconomy's national network. Before joining Xconomy, he was a features editor at New Scientist magazine, where he edited and wrote articles on physics, technology, and neuroscience. Previously he was senior writer at Technology Review, where he reported on emerging technologies, R&D, and advances in computing, robotics, and applied physics. His writing has also appeared in Wired, Nature, and The Atlantic Monthly’s website. He was named a New York Times professional fellow in 2003.
Greg is the co-author of Guanxi (Simon & Schuster, 2006), about Microsoft in China and the global competition for talent and technology. Before becoming a journalist, he did research at MIT’s Artificial Intelligence Lab. He has published 20 papers in scientific journals and conferences and spoken on innovation at Adobe, Amazon, eBay, Google, HP, Microsoft, Yahoo, and other organizations. He has a Master’s and Ph.D. in electrical engineering and computer science from MIT, and a B.S. in electrical engineering from the University of Illinois, Urbana-Champaign.
View all posts by Gregory T. Huang